Spaltudaq (SPAHL-too-dack), the Seattle-based maker of genetically engineered antibody drugs, has changed its name to Theraclone Sciences. Founder Johnny Stine, a member of the Snohomish tribe, gave the company its original name after a healing ceremony once performed by his ancestors in the Puget Sound region to make sure people don’t die before their time. The new name was chosen to “highlight our ability to clone and express clinically relevant, naturally fully human antibodies for clinical and commercial benefit,” said CEO David Fanning.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
